These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32295157)

  • 1. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.
    Vakili H; Koorse Germans S; Dong X; Kansagra A; Patel H; Muthukumar A; Hashim IA
    Diagnostics (Basel); 2020 Apr; 10(4):. PubMed ID: 32295157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A thin-film interferometry-based label-free immunoassay for the detection of daratumumab interference in serum protein electrophoresis.
    Luo YR; Chakraborty I; Zuk RF; Lynch KL; Wu AHB
    Clin Chim Acta; 2020 Mar; 502():128-132. PubMed ID: 31883925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An up-conversion fluorescence lateral-flow immunoassay for rapid detection of Daratumumab in serum protein electrophoresis clinical samples.
    Liu Y; Tao Y; Yeung PS; Lu M; Liu J; Yu F; Shi RZ; Luo RY
    Clin Chim Acta; 2024 Jun; 559():119677. PubMed ID: 38636694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
    Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
    Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
    Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
    Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab.
    Jiang XY; Luider J; Shameli A
    Cytometry B Clin Cytom; 2020 Jan; 98(1):68-74. PubMed ID: 31313879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab.
    Baloda V; Shurin MR; Wheeler SE
    J Appl Lab Med; 2022 Jun; 7(4):910-915. PubMed ID: 35060610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.
    Singh G
    J Clin Med Res; 2017 Aug; 9(8):671-679. PubMed ID: 28725315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
    Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
    Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
    Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
    Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
    Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
    Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolving the daratumumab interference with blood compatibility testing.
    Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
    Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody.
    Aung F; Spencer J; Potter D; Pham TD; Farooqui N; Platt KR; Zayat R; Oliveira M; Smeland-Wagman R; Petersen E; Kaufman RM
    Transfusion; 2022 Aug; 62(8):1511-1518. PubMed ID: 35866570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
    Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
    Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
    Ghose J; Viola D; Terrazas C; Caserta E; Troadec E; Khalife J; Gunes EG; Sanchez J; McDonald T; Marcucci G; Kaur B; Rosenzweig M; Keats J; Rosen S; Krishnan A; Satoskar AR; Hofmeister CC; Pichiorri F
    Oncoimmunology; 2018; 7(10):e1486948. PubMed ID: 30288349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
    Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
    Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.